Benitec Biopharma (BNTC) Depreciation & Amortization (CF) (2019 - 2025)

Benitec Biopharma (BNTC) has disclosed Depreciation & Amortization (CF) for 7 consecutive years, with $14000.0 as the latest value for Q2 2025.

  • Quarterly Depreciation & Amortization (CF) fell 46.15% to $14000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $66000.0 through Jun 2025, down 24.14% year-over-year, with the annual reading at $66000.0 for FY2025, 24.14% down from the prior year.
  • Depreciation & Amortization (CF) hit $14000.0 in Q2 2025 for Benitec Biopharma, up from $13000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $67000.0 in Q1 2021 to a low of $6000.0 in Q2 2022.
  • Historically, Depreciation & Amortization (CF) has averaged $31944.4 across 5 years, with a median of $25500.0 in 2024.
  • Biggest five-year swings in Depreciation & Amortization (CF): tumbled 88.46% in 2022 and later soared 250.0% in 2023.
  • Year by year, Depreciation & Amortization (CF) stood at $55000.0 in 2021, then decreased by 25.45% to $41000.0 in 2022, then tumbled by 58.54% to $17000.0 in 2023, then dropped by 17.65% to $14000.0 in 2024, then changed by 0.0% to $14000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for BNTC at $14000.0 in Q2 2025, $13000.0 in Q1 2025, and $14000.0 in Q4 2024.